NCT07169175 - A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

March 30, 2028

Study Completion Date

September 30, 2028

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Interventions

DRUG

SNUG01

AAV (adeno-associated virus) Gene therapy

Trial Locations (4)

Peking University Third Hospital, Beijing

Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

Fujian Medical University Union Hospital, Fuzhou

Massachusetts General Hospital, Boston

All Listed Sponsors

lead

SineuGene Therapeutics Co., Ltd.

INDUSTRY